伊马替尼布甲酸诱导的急性肝毒性
Imen Frikha1, Yousra Fakhfakh1, Rim Sahnoun2
1Department of Hematology, Hedi Chaker Hospital, University of Sfax, Tunisia.
概括
治疗慢性髓性白血病的伊马替尼可能会导致急性肝损伤. 停用伊马替尼和切换到尼洛替尼导致恢复,突出显示需要监测肝功能.
科学领域:
- 在瘤学瘤学.
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 伊马替尼是慢性髓性白血病 (CML) 的标准治疗方法.
- 伊马替尼布诱导的肝毒性是一种潜在的并发症,但其机制尚不清楚.
- 肝损伤可能会使CML治疗复杂化,并需要改变治疗方法.
研究的目的:
- 在CML患者中报告因伊马替尼治疗而出现的急性毒性肝炎病例.
- 讨论伊马替尼布诱导的肝损伤的管理和结果.
- 强调在伊马替尼治疗期间监测肝功能的重要性.
主要方法:
- 这里介绍了一个51岁的CML男性病人的病例报告.
- 患者在经过5个月的伊马替尼治疗后出现了急性毒性肝炎.
- 停止治疗,并监测肝功能.
主要成果:
- 患者在停止使用伊马替尼布后经历了良好的结果,肝功能在12周内恢复正常.
- 切换到尼洛尼布是很好地耐受,没有不良的肝脏事件.
- 这表明伊马替尼和观察到的肝毒性之间存在因果关系.
结论:
- 定期的肝功能检测对于接受伊马替尼治疗的患者至关重要.
- 如果细胞分解超过正常的上限的五倍,建议停止治疗imaatinib.
- 尼罗丁尼在因伊马替尼引起的肝毒性病例中可能是一个安全的替代品.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
202
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
202
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
261
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
261


